Innovative medications at a limited price, closer to the end

the State Public Health Agency Law It will not bring with it the creation of the Control and Prevention Authority, if it exceeds the year of Congress next week, but it will also mean excluding Additional innovation medications Subordinate The reference price system. It is something that has claimed the drug industry so as not to hide the value -added drug incentive. the Medicines Committee between Medicines You can even “review” the value of innovative medications.

Among the 12 compact transactions in Public Health Agency Bill In the presentation stage – which was raised by the Health Committee last Thursday – there is one based on the ERC proposal to amend Article 98 of Harmings of the Law of Medicines and Right Using. Medicines funded by the national health system (SNSIt is assembled in groups shared in the same active material. These groups include both general or biological medicines that were on the market for a period of 10 years and those that provide improvements in the current drugs to meet uncomfortable needs. The current system sets a homogeneous price for drugs from the same group. That is, it equals the value of creators with the value of the two years and does not recognize the increasing innovation.

Innovative medicines, according to FarmaindustriaIt represents about 40 percent of the drugs that have reached the market in the past decade. He was the innovative pharmaceutical employer On the pretext that additional innovation has favorable financing conditions Because their growth is not discouraged and the therapeutic opportunities are offered to patients they need.

The reform submitted to the law of guarantees in the Public Health Agency Law provides three exceptions to these Reference price groupsOne of them indicates medications that, “due to a new signal, a lower dose, a new pharmaceutical form, a drug feature or any other feature, objectively lead to improved patients or a SNS strategic feature.” In these cases, it is possible, exempt, or exempt from the reference pricing system, or is evaluated with a factor that raises its reference price, but in general to which it belongs.

Moreover, the amendment adds another title to the article of the Medicines Committee between the Medicines, “when the competent body is proposed to the competent body Ministry of Health“The price of the drugs listed in reference groups” can be reviewed in the case of “strategic drugs recognized by the Spanish Agency for Medicines and Health Products (AEMPS) “.

Reform before the future law of medicines

These are the organizational changes that the Ministry of Health planned to include in A new law for medicinesWhich was exposed to the paralysis process awaiting Financial approval for the Ministry of Finance. ERC Special Group has registered an amendment to this organizational project for Excluding innovative drugs from the reference price system. However, the final dates that must be closed on this reform will accelerate with the approval of the Public Health Agency Law, which will happen, with the exception of surprises, next Thursday, in the plenary session Congress.

Other exceptions to the reference price system

In addition to the increasing innovation medications, the aforementioned presentations for treatments in treatments will be outside the reference price system pediatricsThis corresponding to drugs to use the hospital and medicines “taking into account unique reserves” to be dispensed with in Pharmacy services Hospitals. Reform will also require that clinical containers form independent groups and reference groups of drugs derived from human plasma can be formed or those who have an orphan classification.

Other developments are the mandate of the Ministry of Health to organize, through the royal decree, “a price system for healthy products and distribution with the recipe in Pharmacy Office On similar principles, although it is adapted to its properties. ”